TCR2 Therapeutics Inc. (TCRR): Price and Financial Metrics

TCR2 Therapeutics Inc. (TCRR): $1.48

0.09 (-5.73%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add TCRR to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#292 of NR

in industry

TCRR Price/Volume Stats

Current price $1.48 52-week high $3.88
Prev. close $1.57 52-week low $0.82
Day low $1.48 Volume 3,913,300
Day high $1.63 Avg. volume 494,777
50-day MA $1.69 Dividend yield N/A
200-day MA $1.64 Market Cap 58.11M

TCRR Stock Price Chart Interactive Chart >


TCR2 Therapeutics Inc. (TCRR) Company Bio


TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.


TCRR Latest News Stream


Event/Time News Detail
Loading, please wait...

TCRR Latest Social Stream


Loading social stream, please wait...

View Full TCRR Social Stream

Latest TCRR News From Around the Web

Below are the latest news stories about TCR2 THERAPEUTICS INC that investors may wish to consider to help them evaluate TCRR as an investment opportunity.

TCR² Therapeutics: Betting On A Solid Reversal

Thesis

TCR² Therapeutics (TCRR) develops oncology drug candidates.

The company's stock started selling off around last year's September timeframe, leaving TCR² with a 52-week high of $19,03 and a 52-week low of $2,06. The company trades well below cash value at this point. It has a market cap around $140 million, and had $206 million cash in hand at the end of Q2 2022.

Whereas earlier reporting by the company had been perceived as very positive by the market, the sell-off starting in September 2021 may have been caused by a perceived efficacy discrepancy in success between malignant pleural/peritonea...

E. Roudasev on Seeking Alpha | August 18, 2022

Read More 'TCRR' Stories Here

TCRR Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -91.25%
5-year -90.51%
YTD N/A
2023 0.00%
2022 -78.57%
2021 -84.93%
2020 116.60%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!